 |
VasoMedical-BIOX to Exhibit at the 70th China International Medical Equipment Fair |
New MobiCareTM Patient Monitoring System to be Launched
WESTBURY, N.Y. – October 24, 2013 – VasoMedical, Inc. (“VasoMedical”) (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology including EECP® systems, the gold standard of ECP therapy, announced today that BIOX Instruments Co. Ltd., a China-based subsidiary of the Company, will exhibit at the 70th China International Medical Equipment Fair (CMEF Autumn 2013) from November 3-6, 2013 in Xiamen, China. In addition to showcasing its BIOX series of ECG Holter and Ambulatory Blood Pressure Monitoring devices and software, the company will also introduce its new MobiCareTMPatient Monitor.
CMEF Autumn 2013 will take place at the Xiamen International Conference and Exhibition Center. During the four-day event, thousands of products such as medical imaging, electronics, first aid, rehabilitation, nursing, medical information technology and outsourcing services will be showcased. Additionally, CMEF provides services to the entire medical industry supply chain and has become the biggest exhibition of medical equipment related products and services in the Asia-Pacific region, with over 1 million square feet of exhibition space for more than 2,600 exhibitors and attracting over 82,000 visitors from 125 countries and regions.
The MobiCareTm Patient Monitor that VasoMedical will introduce during the event is a multi-parameter patient monitor for bedside use and/or telemetry applications. It wirelessly transmits all patient vital signs, including ECG, respiration, SpO2, temperature and NIBP, to a bedside receiver or a tablet display, enabling patient mobility with comfort and at the same time providing ease of use to the medical staff. Its compact and flexible design allows for various configurations in the product line to meet specific needs of different clinical environments, such as bedside patient monitoring, supervised exercise in cardiac rehabilitation, community and home care of patients with chronic disease. With a pending approval from the China State FDA, the MobiCareTM product line will be first introduced to the Chinese market, following which the company intends to pursue CE Mark and US FDA clearance.
“The medical device industry has been growing rapidly in China and CMEF provides an ideal platform to launch new, unique and innovative products. It also enables us to reach out to our existing customers as well as develop future customer base in China and the world market,” said Qiuming Shen, President of BIOX Instruments Co. Ltd. “The MobiCareTM product line once again demonstrated our technological superiority in miniaturization and low power-consumption medical devices, and its introduction to the marketplace greatly enhances our existing product portfolio. We will continue to communicate with leading healthcare professionals and the medical equipment industry about our company and the value proposition our products offer so that more patients around the world can benefit from our great products.”
VasoMedical will be located at Booth MF20.
About VasoMedical
VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company's main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, VasoMedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; VasoMedical Global operates the Company's China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company's website at www.vasomedical.com.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com
Media Contacts:
Samantha Wolf / Andrew Herweg
KCSA Strategic Communications
212-896-1220 / 212-896-1273
swolf@kcsa.com / aherweg@kcsa.com